What is MiMedx Group, Inc.'s (MDXG) StockRank?

MoatMap's StockRank for MiMedx Group, Inc. (MDXG) is 65/100, with a Buy signal. This is a composite score combining Quality (78), Value (59), and Momentum (16) factor ranks across MoatMap's 19,000+ stock universe.

Does MiMedx Group, Inc. have an economic moat?

MiMedx Group, Inc. (MDXG) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is MiMedx Group, Inc. a buy, hold, or sell?

MoatMap's current signal for MiMedx Group, Inc. (MDXG) is Buy, based on a StockRank of 65/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is MiMedx Group, Inc. in?

MiMedx Group, Inc. (MDXG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

MDXG

BUYREMOVE

MiMedx Group, Inc. · Healthcare · United States · $547M · Avg Vol: $5M/d

StockRank

P/E (TTM)

18.0x

ROE

13.8%

D/E

0.1x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

MiMedx has solid quality metrics (Q score of 79) but suffers from extremely weak momentum (M score of 11) and lacks a strong, secular macro tailwind to catalyze an asymmetric re-rating over our 18-month horizon.

COMPANY DESCRIPTION

MiMedx Group, Inc. is a biopharmaceutical company specializing in the development and commercialization of regenerative and therapeutic biologics derived from human placental tissue. Its proprietary allograft products, including AmnioFix and EpiFix, hold a leading position in advanced wound care and surgical recovery markets, backed by extensive clinical evidence and patent-protected processing technologies. MiMedx is a pioneer in regenerative medicine, offering innovative solutions for complex medical conditions.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	268M	321M	349M	419M	16.1%
EPS	-0.33	0.40	0.29	0.33	-9.2%
Shares	114M	146M	147M	148M	+30.2%
Debt	49M	49M	19M	18M	-28.2%
Equity	-18M	143M	193M	257M	34.1%
Op CF	-18M	27M	66M	74M	66.2%
Inv CF	-3M	-2M	-10M	-7M	—
Fin CF	-580,000	-9M	-34M	-5M	—

PRICE (1M)-2.2%

SMA 50SMA 200

$3.60

RSI (14)

48.8

52W High

$7.99

From 52W High

0.5%

SCORE BREAKDOWN

Quality

ROIC

22.9%93.4

ROE

13.8%80.3

GP/Assets

92.1%96.8

Op. Margin

-27.2%24.9

FCF/Assets

17.8%94.8

Piotroski

—83.5

Int. Cover

—N/A

D/E Ratio

0.07x70.1

Current Ratio

5.39x72.8

Value

P/E (TTM)

18.0x62.9

EV/EBITDA

7.5x50.7

P/FCF

9.0x85.2

P/B

2.1x54.1

P/S

1.4x78.0

Div Yield

—N/A

Momentum

52W High %

45%18.4

RS 6M

-57%18.9

SMA 50/200

0.65x3.6

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

-39%10.5

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$547M

P/E (Forward)

29.4x

Gross Margin

81.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MDXG are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
MDXG	MiMedx Group, Inc.(you)	$547M	65	BUY
CADL	Candel Therapeutics, Inc.	$593M	58	HOLD
TECX	Tectonic Therapeutic, Inc.	$562M	56	HOLD
FENC	Fennec Pharmaceuticals Inc.	$344M	67	BUY
ABEO	Abeona Therapeutics Inc.	$329M	66	BUY
RLMD	Relmada Therapeutics, Inc.	$760M	59	HOLD
TBPH	Theravance Biopharma, Inc.	$836M	72	BUY
IPSC	Century Therapeutics, Inc.	$430M	55	HOLD
MGTX	MeiraGTx Holdings plc	$926M	59	HOLD
IMMX	Immix Biopharma, Inc.	$629M	48	HOLD

Peer medians: ROE -22.6% · P/E 25.3x · Gross margin 44.2%

MiMedx Group, Inc. (MDXG) — Stock Score Summary

MiMedx Group, Inc. (MDXG) has a MoatMap StockRank of 65/100 based on Quality (78/100), Value (59/100), and Momentum (16/100) factor scores. The current signal is BUY. MiMedx has solid quality metrics (Q score of 79) but suffers from extremely weak momentum (M score of 11) and lacks a strong, secular macro tailwind to catalyze an asymmetric re-rating over our 18-month horizon.

Key Financial Metrics

Price	$3.60
Market Cap	$547M
P/E (TTM)	18.00
P/E (Forward)	29.39
Price/Book	2.08
Return on Equity	13.8%
Return on Invested Capital	22.9%
Debt/Equity	7.24
Gross Margin	81.0%
Operating Margin	-27.2%
Revenue Growth	-33.1%
Free Cash Flow	$61M

MiMedx Group, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is MiMedx Group, Inc.’s (MDXG) StockRank?: MoatMap’s StockRank for MiMedx Group, Inc. (MDXG) is 65/100, with a Buy signal. It is a composite of Quality (78), Value (59), and Momentum (16) factor ranks across MoatMap’s 19,000+ stock universe.
Does MiMedx Group, Inc. have an economic moat?: MiMedx Group, Inc. (MDXG) has a Quality factor score of 78/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is MiMedx Group, Inc. a buy, hold, or sell?: MoatMap’s current signal for MiMedx Group, Inc. (MDXG) is Buy, based on a StockRank of 65/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is MiMedx Group, Inc. in?: MiMedx Group, Inc. (MDXG) operates in the Healthcare sector, specifically the Biotechnology industry (United States).